semaglutide laredo tx Valley Weight Loss Discover the benefits of our

But we must also consider possible long-term health benefits and cost savings as an important part of this equation, and the value of these drugs to patients health outcomes. Commercial insurance coverage for GLP-1 drugs is typically approved on a limited time basis, potentially several months to two years, and weight loss must be documented to maintain coverage, according to the commission

doi: 10.1001/jamanetworkopen.2023.27739 [PubMed] 38431210 Stewart GW

Participants achieved significant reductions that exceeded results from existing dual agonists

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)

Review the holdings, adjust the criteria, or customize the portfolio further to match your investment thesis